导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.21% | 1709/4773 |
| 近一周 | -2.08% | 1184/5462 |
| 近一月 | -3.59% | 1846/5421 |
| 近一季 | -8.12% | 2699/5209 |
| 近半年 | -6.24% | 3054/4920 |
| 近一年 | 9.10% | 1123/4366 |
| 近两年 | 69.26% | 989/2954 |
| 近三年 | 42.86% | 658/2253 |
| 成立以来 | 163.94% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.38% 1295/4961 |
14.20% 1859/5312 |
- - |
- - |
| 2025 | 31.23% 1256/4813 |
1.26% 1664/3635 |
5.09% 652/4076 |
18.40% 2304/4524 |
4.16% 565/4813 |
| 2024 | 9.53% 1461/3463 |
0.21% 1022/2808 |
-3.03% 1290/3014 |
11.73% 2471/3129 |
0.89% 1155/3463 |
| 2023 | 3.18% 292/2656 |
9.12% 425/2280 |
-0.95% 431/2385 |
-1.91% 598/2515 |
-2.68% 510/2655 |
| 2022 | -10.41% 204/2207 |
-12.55% 629/1919 |
3.92% 1075/2016 |
-6.12% 92/2113 |
5.01% 495/2208 |
| 2021 | 30.07% 69/1822 |
8.64% 61/1255 |
14.77% 245/1330 |
2.78% 429/1466 |
1.50% 903/1822 |
| 2020 | - - |
- - |
- - |
14.36% 281/1164 |
4.20% 856/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏中证500指数增强A VS. 长安沪深300非周期A(740101) |